Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma

As part of the 2019 ASH Meeting on Hematologic Malignancies held September 6-7 in Chicago, experts were invited to discuss challenging patient care questions,...

European Commission Approves Elotuzumab Triplet for Multiple Myeloma

The European Commission (EC) has approved elotuzumab plus pomalidomide and low-dose dexamethasone (EPd) to treat relapsed and refractory multiple myeloma in adult patients who...
On location

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

The combination of isatuximab and pomalidomide plus dexamethasone (Pd) extended progression-free survival (PFS) to 11.5 months in patients with relapsed/refractory multiple myeloma (MM) –...
On location

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
WIB_icon

Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...

If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...

Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma

In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...

FDA Grants Selinexor Accelerated Approval Despite Concerns With Trial Data

The U.S. Food and Drug Administration (FDA) granted accelerated approval to for selinexor, an oral selective inhibitor of nuclear export (SINE), for patients with...

FDA Lifts Partial Clinical Hold on Venetoclax Trial in Myeloma

Researchers can move forward with the phase III CANOVA trial, now that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical...

FDA Approves Daratumumab for Patients with Transplant-Ineligible Myeloma

On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab, in combination with lenalidomide and dexamethasone, for patients with newly diagnosed...

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

SHARE